• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

应用 AlphaFold 结构和生成模型发现新型选择性 SIK2 抑制剂。

Discovery of novel and selective SIK2 inhibitors by the application of AlphaFold structures and generative models.

机构信息

Insilico Medicine Shanghai Ltd., Shanghai 201203, China.

Insilico Medicine AI Limited, Masdar City, Abu Dhabi 145748, UAE.

出版信息

Bioorg Med Chem. 2023 Aug 15;91:117414. doi: 10.1016/j.bmc.2023.117414. Epub 2023 Jul 13.

DOI:10.1016/j.bmc.2023.117414
PMID:37467565
Abstract

Salt-inducible kinase 2 (SIK2) has been recognized as a potential target for anti-inflammation and anti-cancer therapy. In this paper, based on the binding pose of the reported compound (GLPG-3970, 3) with AlphaFold protein structure, a series of hinge cores were generated via AI-generative models (Chemistry42). After the molecular docking, synthesis, and biological evaluation, a hit molecule (7f) targeting SIK2 was obtained with a novel scaffold. Further SAR exploration led to the discovery of compound 8g with superior potency against SIK2 compared with the reported inhibitors. Furthermore, 8g also demonstrated excellent selectivity over other AMPK kinases, favorable in vitro ADMET profiles and decent cellular activities. This work provides an alternative approach to the discovery of novel and selective kinase inhibitors.

摘要

盐诱导激酶 2(SIK2)已被认为是抗炎和抗癌治疗的潜在靶点。在本文中,基于报道的化合物(GLPG-3970,3)与 AlphaFold 蛋白结构的结合构象,通过人工智能生成模型(Chemistry42)生成了一系列铰链核心。经过分子对接、合成和生物评价,得到了一种以新型骨架为靶点的 SIK2 命中分子(7f)。进一步的 SAR 探索导致发现了化合物 8g,其对 SIK2 的活性优于报道的抑制剂。此外,8g 对其他 AMPK 激酶也表现出优异的选择性,具有良好的体外 ADMET 特性和良好的细胞活性。这项工作为发现新型和选择性激酶抑制剂提供了一种替代方法。

相似文献

1
Discovery of novel and selective SIK2 inhibitors by the application of AlphaFold structures and generative models.应用 AlphaFold 结构和生成模型发现新型选择性 SIK2 抑制剂。
Bioorg Med Chem. 2023 Aug 15;91:117414. doi: 10.1016/j.bmc.2023.117414. Epub 2023 Jul 13.
2
Exploring the stability of inhibitor binding to SIK2 using molecular dynamics simulation and binding free energy calculation.利用分子动力学模拟和结合自由能计算探索抑制剂与SIK2结合的稳定性。
Phys Chem Chem Phys. 2021 Jun 16;23(23):13216-13227. doi: 10.1039/d1cp00717c.
3
AlphaFold accelerates artificial intelligence powered drug discovery: efficient discovery of a novel CDK20 small molecule inhibitor.AlphaFold加速人工智能驱动的药物发现:高效发现新型CDK20小分子抑制剂。
Chem Sci. 2023 Jan 10;14(6):1443-1452. doi: 10.1039/d2sc05709c. eCollection 2023 Feb 8.
4
Optimization of Selectivity and Pharmacokinetic Properties of Salt-Inducible Kinase Inhibitors that Led to the Discovery of Pan-SIK Inhibitor GLPG3312.盐诱导激酶抑制剂的选择性和药代动力学性质的优化导致了泛 SIK 抑制剂 GLPG3312 的发现。
J Med Chem. 2024 Jan 11;67(1):380-401. doi: 10.1021/acs.jmedchem.3c01428. Epub 2023 Dec 26.
5
Salt-inducible kinase 2 regulates mitotic progression and transcription in prostate cancer.盐诱导激酶2调节前列腺癌中的有丝分裂进程和转录。
Mol Cancer Res. 2015 Apr;13(4):620-635. doi: 10.1158/1541-7786.MCR-13-0182-T. Epub 2014 Dec 29.
6
Discovery of Clinical Candidate GLPG3970: A Potent and Selective Dual SIK2/SIK3 Inhibitor for the Treatment of Autoimmune and Inflammatory Diseases.发现临床候选药物 GLPG3970:一种强效和选择性的双重 SIK2/SIK3 抑制剂,用于治疗自身免疫和炎症性疾病。
J Med Chem. 2024 Apr 11;67(7):5233-5258. doi: 10.1021/acs.jmedchem.3c02246. Epub 2024 Mar 29.
7
Designing of potent anti-diabetic molecules by targeting SIK2 using computational approaches.通过计算方法靶向 SIK2 设计有效的抗糖尿病分子。
Mol Divers. 2023 Jun;27(3):1101-1121. doi: 10.1007/s11030-022-10470-0. Epub 2022 Jun 21.
8
The AMPK-related kinase SIK2 is regulated by cAMP via phosphorylation at Ser358 in adipocytes.AMPK 相关激酶 SIK2 通过在脂肪细胞中 Ser358 的磷酸化作用受 cAMP 调节。
Biochem J. 2012 Jun 15;444(3):503-14. doi: 10.1042/BJ20111932.
9
Structure-based design of selective, orally available salt-inducible kinase inhibitors that stimulate bone formation in mice.基于结构的设计,选择性、口服盐诱导激酶抑制剂,刺激小鼠骨形成。
Proc Natl Acad Sci U S A. 2022 Dec 13;119(50):e2214396119. doi: 10.1073/pnas.2214396119. Epub 2022 Dec 6.
10
Discovery of a Potent Dual SLK/STK10 Inhibitor Based on a Maleimide Scaffold.基于马来酰亚胺骨架的强效双重 SLK/STK10 抑制剂的发现。
J Med Chem. 2021 Sep 23;64(18):13259-13278. doi: 10.1021/acs.jmedchem.0c01579. Epub 2021 Aug 31.

引用本文的文献

1
Generative Deep Learning for de Novo Drug Design─A Chemical Space Odyssey.用于从头药物设计的生成式深度学习——一场化学空间奥德赛。
J Chem Inf Model. 2025 Jul 28;65(14):7352-7372. doi: 10.1021/acs.jcim.5c00641. Epub 2025 Jul 9.
2
Accelerating discovery of bioactive ligands with pharmacophore-informed generative models.利用药效团信息生成模型加速生物活性配体的发现。
Nat Commun. 2025 Mar 10;16(1):2391. doi: 10.1038/s41467-025-56349-0.
3
Understanding the roles of salt-inducible kinases in cardiometabolic disease.了解盐诱导激酶在心脏代谢疾病中的作用。
Front Physiol. 2024 Jul 16;15:1426244. doi: 10.3389/fphys.2024.1426244. eCollection 2024.
4
PandaOmics: An AI-Driven Platform for Therapeutic Target and Biomarker Discovery.熊猫组学:一个人工智能驱动的治疗靶点和生物标志物发现平台。
J Chem Inf Model. 2024 May 27;64(10):3961-3969. doi: 10.1021/acs.jcim.3c01619. Epub 2024 Feb 25.
5
Comparative Structure-Based Virtual Screening Utilizing Optimized AlphaFold Model Identifies Selective HDAC11 Inhibitor.利用优化的AlphaFold模型进行基于结构的比较虚拟筛选,鉴定出选择性HDAC11抑制剂。
Int J Mol Sci. 2024 Jan 22;25(2):1358. doi: 10.3390/ijms25021358.